Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 19;14(4):355-356.
doi: 10.1136/flgastro-2022-102288. eCollection 2023.

Measuring patient experience of Cytosponge using the Newcastle ENDOPREM

Laura Jane Neilson  1   2 , Rebecca C Fitzgerald  3   4 , Jennifer Deane  2 , Irene Debiram-Beecham  3 , Linda Sharp  2 , Colin J Rees  1   2
Affiliations

Measuring patient experience of Cytosponge using the Newcastle ENDOPREM

Laura Jane Neilson et al. Frontline Gastroenterol. .
No abstract available

Keywords: BARRETT'S OESOPHAGUS; ENDOSCOPY; GASTROESOPHAGEAL REFLUX DISEASE.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LJN, LS and CR have received grant funding from Medtronic. LS and CR have received grant funding from 3D Matrix solutions. CJR has received grant funding from ARC medical, Norgine and Olympus medical. He was an expert witness for ARC medical and Olympus medical. RCF is named on patents related to Cytosponge and associated assays that have been licensed to Covidien (now Medtronic). RCF is a founder and <8% shareholder of Cyted Ltd. ID-B and JD have no conflicts to declare.

References

    1. Ross-Innes CS, Debiram-Beecham I, O'Donovan M, et al. . Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med 2015;12:e1001780. 10.1371/journal.pmed.1001780 - DOI - PMC - PubMed
    1. Fitzgerald RC, di Pietro M, O'Donovan M, et al. . Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet 2020;396:333–44. 10.1016/S0140-6736(20)31099-0 - DOI - PMC - PubMed
    1. Pilonis ND, Killcoyne S, Tan WK, et al. . Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett’s oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot. Lancet Oncol 2022;23:270–8. 10.1016/S1470-2045(21)00667-7 - DOI - PMC - PubMed
    1. Rees CJ, Trebble TM, Von Wagner C, et al. . British Society of gastroenterology position statement on patient experience of GI endoscopy. Gut 2020;69:1718.1–9. 10.1136/gutjnl-2019-319207 - DOI - PubMed
    1. Neilson LJ, Patterson J, von Wagner C, et al. . Patient experience of gastrointestinal endoscopy: informing the development of the Newcastle ENDOPREM™. Frontline Gastroenterol 2020;11:209–17. 10.1136/flgastro-2019-101321 - DOI - PMC - PubMed

LinkOut - more resources